Jump to Main Content

Programs

Product Theaters

A New Treatment Option for Patients with Acute Myeloid Leukemia

Sponsored by Bristol Myers Squibb

Saturday, December 5, 2020, 11:00 a.m. - 12:00 p.m. Pacific time

Speaker:

Michelle Little, PhD
Bristol Myers Squibb

back to top

Study Results from the First and Only Randomized Pivotal Trial in R/R DLBCL

Sponsored by Genentech

Saturday, December 5, 2020, 11:00 a.m. - 12:00 p.m. Pacific time

Speaker:

Lisa Musick, PharmD, BCPS
Genentech

back to top

Introducing BLENREP (belantamab mafodotin-blmf) for Injection, for Intravenous Use

Sponsored by GSK

Saturday, December 5, 2020, 11:00 a.m. - 12:00 p.m. Pacific time

Speaker:

Allison Doherty
GSK

back to top

A Discussion of Efficacy and Safety on a Treatment Option for Adults With Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)

Sponsored by Pfizer

Saturday, December 5, 2020, 11:00 a.m. - 12:00 p.m. Pacific time

Speaker:

Richa Shah, PharmD
Pfizer

back to top

Advances in the Treatment of aTTP

Sponsored by Sanofi Genzyme

Saturday, December 5, 2020, 11:00 a.m. - 12:00 p.m. Pacific time

Speaker:

Yu Chen Barrett, PhD
Sanofi Genzyme

back to top

NGS Solutions That Help Simplify Your Journey to Answers in Hemato-Oncology Research

Sponsored by Thermo Fisher Scientific

Saturday, December 5, 2020, 11:00 a.m. - 12:00 p.m. Pacific time

Speaker:

Amy Carroll, PhD
Thermo Fisher Scientific

back to top

A Targeted Therapeutic Approach for Relapsed or Refractory FLT3m+ AML Patients

Sponsored by Astellas Pharma US, Inc

Sunday, December 6, 2020, 11:00 a.m. - 12:00 p.m. Pacific time

Speaker:

Ramon V. Tiu, MD
Astellas Pharma US, Inc.

back to top

A Treatment Option for Patients with Myelodysplastic Syndromes

Sponsored by Bristol Myers Squibb

Sunday, December 6, 2020, 11:00 a.m. - 12:00 p.m. Pacific time

Speaker:

Jeffrey A. Jones, MD, MPH
Bristol Myers Squibb

back to top

Review of Efficacy and Safety of Monjuvi (tafasitamab-cxix) : FDA-Approved Monoclonal Antibody in Combination with Lenalidomide for Adult Patients with R/R DLBCL Who Have Received at Least One Prior Therapy

Sponsored by Incyte Corporation

Sunday, December 6, 2020, 11:00 a.m. - 12:00 p.m. Pacific time

Speaker:

Susan Snodgrass, MD
Incyte Corporation

back to top

Redefining Approaches in Early-Line Multiple Myeloma Treatment

Sponsored by Janssen Biotech, Inc

Sunday, December 6, 2020, 11:00 a.m. - 12:00 p.m. Pacific time

Speaker:

Kathleen Gray, PhD
Janssen Scientific Affairs

back to top

Developing the Future of CAR-T Cell Therapy Today

Sponsored by Novartis Pharmaceuticals

Sunday, December 6, 2020, 11:00 a.m. - 12:00 p.m. Pacific time

Speakers:

Amir Hefni, PhD
Novartis

Carolin Barth, MD
Novartis

back to top

A Treatment Option for Adult Patients With Newly Diagnosed CP Ph+ CML or Patients With CML Resistant/Intolerant to Prior TKI Therapy

Sponsored by Pfizer

Sunday, December 6, 2020, 11:00 a.m. - 12:00 p.m. Pacific time

Speaker:

Jasmeet Anand, PharmD
Pfizer

back to top

An Anti-CD38 Directed Antibody for the Treatment for Appropriate Patients with Relapsed Refractory Multiple Myeloma

Sponsored by Sanofi Genzyme

Sunday, December 6, 2020, 11:00 a.m. - 12:00 p.m. Pacific time

Speaker:

Megan Sell, NP
Sanofi Genzyme

back to top

Exploring Outcomes With Fixed-Duration Treatment in CLL and New Evidence in First-Line AML: Pivotal Clinical Trial Data That Supports Treatment Decisions and Patient Care

Sponsored by Abbvie

Monday, December 7, 2020, 10:30 a.m. - 11:30 a.m. Pacific time

Speaker:

R. Frank Cornell, MD, MS
AbbVie

back to top

clonoSEQ and MRD Assessment in the Management of Lymphoid Malignancies

Sponsored by Adaptive Biotechnologies

Monday, December 7, 2020, 10:30 a.m. - 11:30 a.m. Pacific time

Speaker:

Lanny R. Kirsch, MD
Adaptive Biotechnologies

back to top

PNH: Key Clinical Considerations for a Terminal Complement-Mediated Disease

Sponsored by Alexion Pharmaceuticals

Monday, December 7, 2020, 10:30 a.m. - 11:30 a.m. Pacific time

Speaker:

Anita Hill, MD, PhD
Alexion Pharmaceuticals, Inc.

back to top

Scientific Exploration of Novel Targets for Hematology: A Glimpse into Areas of Research and Development

Sponsored by AstraZeneca

Monday, December 7, 2020, 10:30 a.m. - 11:30 a.m. Pacific time

Speakers:

Katharina Modelska, MD, PhD
FibroGen

Anas Younes, MD
AstraZeneca

Priti Patel, MD
AstraZeneca

Andrew Mortlock, PhD
AstraZeneca

Raoul Tibes, MD, PhD
AstraZeneca

Farzana Walcott
AstraZeneca

back to top

Epcoritamab, a Novel Subcutaneous Bi-Specific CD3xCD20 Antibody for the Treatment of Patients with B-NHL: From Bench to Bedside and Beyond

Sponsored by Genmab

Monday, December 7, 2020, 10:30 a.m. - 11:30 a.m. Pacific time

Speaker:

Tahamtan Ahmadi, MD, PhD
Genmab US, Inc

back to top

Trust the Experience of a rFVIIa Product Used for a Wide Range of Indications

Sponsored by Novo Nordisk

Monday, December 7, 2020, 10:30 a.m. - 11:30 a.m. Pacific time

Speaker:

Stephanie Seremetis, MD
Novo Nordisk

back to top

IMBRUVICA® in Frontline CLL/SLL: A Case-based Approach

Sponsored by Pharmacyclics LLC, An AbbVie Company

Monday, December 7, 2020, 10:30 a.m. - 11:30 a.m. Pacific time

Speaker:

Imran Khan, MD
Janssen Biotech, Inc.